Stellungnahme der DGVS zur frühen Nutzenbewertung

Eckart Schott, Berlin 

• Literatur

• 1 Vermehren J, Schlosser B, Domke D. et al. High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. Plos One 2012 7. epub ahead of print
• 2 Razavi H, Waked I, Sarrazin C. et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014; 21: 34-59
• 3 Poethko-Muller C, Zimmermann R, Hamouda O. et al. Epidemiology of hepatitis A, B, and C among adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2013; 56: 707-715
• 4 Wedemeyer H, Duberg AS, Buti M. et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21: 60-89
• 5 https://www.dgvs.de/wissen-kompakt/leitlinien/leitlinien-der-dgvs/hepatitis-c/
• 6 Bourlière M, Gordon SC, Flamm SL. POLARIS-1 and POLARIS-4 Investigators. et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017; 376: 2134-2146 . doi:10.1056/NEJMoa1613512
• 7 de Lédinghen V, Laforest C, Hézode C. et al. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. Clin Infect Dis 2017; DOI: 10.1093/cid/cix916.
• 8 Poordard F. et al. QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir, AASLD 2015; LB-20 (keine Vollpublikation vorhanden).